<!DOCTYPE html><html prefix="og: http://ogp.me/ns#" lang="zh">
<!-- Mirrored from cn.nytimes.com/business/20201207/china-vaccine-astrazeneca/ by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 28 Jan 2022 14:09:06 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head><meta charset="UTF-8"><!-- Browser render  --><meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"><meta name="renderer" content="webkit"><!-- End Browser render --><meta name="keywords" content=""><meta name="description" content="康泰将成为阿斯利康新冠疫苗在中国大陆的独家生产商，也在测试自己的疫苗。但中国疫苗行业饱受腐败和争议困扰，康泰及其老板杜伟民更是身处多起丑闻中心。"><meta id="uuid" name="uuid" content="933bd98d0b2d75f1d07176d403950d7b"><meta id="headline" name="headline" content="中国“疫苗之王”：成功与财富幕布下的丑闻与争议 - 世界经济观察报中文网"><meta id="byline" name="byline" content="黄瑞黎,赫海威"><meta id="date" name="date" content="2020-12-08T09:53:20.000Z"><link rel="alternate" href="index.html" hreflang="zh-Hans"><link rel="alternate" href="zh-hant/index.html" hreflang="zh-Hant"><link rel="alternate" href="https://www.nytimes.com/2020/12/07/business/china-vaccine-astrazeneca.html" hreflang="en-us"><link rel="canonical" href="index.html"><link rel="alternate" type="application/rss+xml" href="https://cn.nytimes.com/rss/"><meta name="apple-itunes-app" content="app-id=807498298, app-argument=nytimescn://article:933bd98d0b2d75f1d07176d403950d7b"><meta name="lang" property="lang" content="zh-cmn-hans"><!-- Apple IOS safari private meta --><link rel="apple-touch-icon-precomposed" sizes="144×144" href="../../../../static01.nyt.com/images/icons/ios-ipad-144x144.png"><link rel="apple-touch-icon-precomposed" sizes="114×114" href="../../../../static01.nyt.com/images/icons/ios-iphone-114x144.png"><link rel="apple-touch-icon-precomposed" href="../../../../static01.nyt.com/images/icons/ios-default-homescreen-57x57.png"><meta name="apple-mobile-web-app-title" content="中国“疫苗之王”：成功与财富幕布下的丑闻与争议 - 世界经济观察报中文网"><meta name="apple-mobile-web-app-capable" content="yes"><!-- End Apple IOS safari private meta --><!-- Viewport and mobile --><meta name="viewport" content="width=device-width,initial-scale=1,user-scalable=no,maximum-scale=1,minimum-scale=1,minimal-ui"><!-- End viewport and mobile --><meta http-equiv="Cache-Control" content="no-siteapp"><meta name="format-detection" content="telephone=no"><meta name="HandheldFriendly" content="true"><meta name="MobileOptimized" content="320"><meta name="x5-orientation" content="portrait"><meta name="full-screen" content="yes"><meta name="x5-fullscreen" content="true"><meta name="browsermode" content="application"><meta name="x5-page-mode" content="app"><meta name="msapplication-tap-highlight" content="no"><meta property="og:title" content="中国“疫苗之王”：成功与财富幕布下的丑闻与争议"><meta property="og:type" content="article"><meta property="og:url" content="index.html"><meta property="og:description" content="康泰将成为阿斯利康新冠疫苗在中国大陆的独家生产商，也在测试自己的疫苗。但中国疫苗行业饱受腐败和争议困扰，康泰及其老板杜伟民更是身处多起丑闻中心。"><meta property="og:site_name" content="世界经济观察报中文网"><meta property="article:publisher" content="https://www.facebook.com/nytimeschinese"><meta property="article:published_time" content="2020-12-08T09:53:20.000Z"><meta property="fb:pages" content="354478527979178"><meta property="fb:app_id" content="1752616314982485"><meta property="og:image" content="../../../../static01.nyt.com/images/2020/12/04/business/00China-vaccine-illo/00China-vaccine-illo-videoLarge.html"><meta property="twitter:card" content="summary_large_image"><meta property="twitter:url" content="index.html"><meta property="twitter:title" content="中国“疫苗之王”：成功与财富幕布下的丑闻与争议"><meta property="twitter:description" content="康泰将成为阿斯利康新冠疫苗在中国大陆的独家生产商，也在测试自己的疫苗。但中国疫苗行业饱受腐败和争议困扰，康泰及其老板杜伟民更是身处多起丑闻中心。"><meta property="twitter:domain" content="cn.nytimes.com"><meta property="twitter:site" content="@nytchinese"><meta property="twitter:creator" content="@nytchinese"><meta property="twitter:image:src" content="../../../../static01.nyt.com/images/2020/12/04/business/00China-vaccine-illo/00China-vaccine-illo-videoLarge.html"><meta name="PT" content="article"><meta name="PST" content="News"><meta name="CG" content="business"><meta name="SCG" content=""><meta name="sourceApp" content="nyt-china-web"><meta name="ptime" content="20201207072043"><meta name="utime" content="20201208095320"><meta name="pdate" content="20201208"><meta name="dat" content="Dec. 07, 2020"><meta name="hdl" content="中国“疫苗之王”：成功与财富幕布下的丑闻与争议"><meta name="byl" content="黄瑞黎,赫海威"><meta name="lp" content="康泰将成为阿斯利康新冠疫苗在中国大陆的独家生产商，也在测试自己的疫苗。但中国疫苗行业饱受腐败和争议困扰，康泰及其老板杜伟民更是身处多起丑闻中心。"><link rel="shortcut icon" href="https://static01.nyt.com/favicon.ico"><link rel="stylesheet" href="../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/nytcn_core/style-flex.min619b.css?v=f1810d8"><link rel="stylesheet" href="../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/web/style.min619b.css?v=f1810d8"><link rel="stylesheet" href="../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/nytcn_core/article.min619b.css?v=f1810d8"><link rel="stylesheet" href="../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/slideshow/slideshow.min619b.css?v=f1810d8"><link rel="stylesheet" href="../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/cookie-banner/style.min619b.css?v=f1810d8"><title>中国“疫苗之王”：成功与财富幕布下的丑闻与争议 - 世界经济观察报中文网</title></head><script>var js_static_path = "https://d1f1eryiqyjs0r.cloudfront.net/js";
 var imgs_static_path = "https://d1f1eryiqyjs0r.cloudfront.net/style/imgs";
 var style_static_path = "https://d1f1eryiqyjs0r.cloudfront.net/style";
 var site = 1;
 var sectionName = "business";
 var adTyp = "art";
 var cookieString = {
     "title": "您的跟踪器设置",
     "headline": "我们使用 cookie 做什么？",
     "summary": '<p>我们利用cookies和类似的技术识别您的重复访问和偏好。我们还使用它们来衡量广告系列的效果，定位广告并分析和网站流量。更多关于cookies的信息（包括如何停用），<a id="JSCookiePolicyLink" href="https://www.nytimes.com/zh-hans/privacy/cookie-policy" rel="noreferrer noopener" target="_blank" data-testid="GDPR-policy">请查看我们的“Cookie政策”</a>。</p><p>自2020年7月20日起，我们将根据您在我们服务中所访问的内容类型向您显示我们认为与您的兴趣相关的广告。您可以<a href="https://www.nytimes.com/zh-hans/privacy/cookie-policy#how-do-i-manage-trackers" rel="noreferrer noopener" target="_blank" data-testid="GDPR-objection">提出反对</a>。希望了解更多信息，请参见我们的<a href="https://nytimes.com/zh-hans/privacy/privacy-policy#we-allow-for-personalized-advertising-on-times-services" rel="noreferrer noopener" target="_blank" data-testid="GDPR-privacy">隐私政策</a>。</p><p>通过在此处点击“我接受”或者“X”，您将被视为同意使用cookies。您随时可以通过我们的Cookie政策来更改您的跟踪器偏好。</p>',
     "button": "接受",
     "trackerButton": "您的跟踪器设置",
     "rejectButton": "拒绝所有",
     "lang": 'zh-hans',
     "trackerLink": "https://www.nytimes.com/zh-hans/privacy/cookie-policy",
 };
 var purrString = {
     "button": "请勿出售我的个人信息",
     "snackbar": "你的设置已经保存在此浏览器和设备上。如果你清除了 cookie，这些设置也会被清除。",
     "snackbarError": "Something went wrong",
     "optedOutText": "我们不再出售您的个人信息",
     "CFALinkText": "California Notices",
     "purrPopupTitle": "Your request to not sell your data will be stored for this browser and device",
     "purrPopupSummary": "If you clear your cookies, your preference will be forgotten. As a California resident, you have additional rights under the California Consumer Privacy Act of 2018. While The New York Times Company does not “sell” personal information of its readers as the term “sell” is traditionally understood, “sell” under the CCPA is broadly defined. To learn more, review the text below.",
     "purrPopupButton": "DISMISS",
     "purrPopupScrollContent": '<p>The New York Times Company does not sell personal information of its readers as the term “sell” is traditionally understood. But “sell” under the CCPA is broadly defined. It includes the sharing of personal information with third parties in exchange for something of value, even if no money changes hands. For example, sharing an advertising or device identifier to a third party may be considered a “sale” under the CCPA. </p><p>To the extent The New York Times Company “sells” your personal information (as the term “sell” is defined under the CCPA), you have the right to opt-out of that “sale” on a going-forward basis at any time. To exercise this right, click the “Do Not Sell My Personal Information” link in the footer of our website or under your “Account,” which you have already done. You can also submit a request to opt-out by emailing us at privacy@nytimes.com with the subject line “California Resident - Do Not Sell.”</p><p>Once you have opted out, you will see a change to “We No Longer Sell Your Personal Information.” If you have an account with certain Times Services (specifically nytimes.com, cooking.nytimes.com, nytimes.com/crosswords, the New York Times app, the New York Times Cooking app and the New York Times Crossword app) and are logged in, we will save your preference and honor your opt-out request across browsers and devices so long as you remain logged in. If you are not logged in, or do not have an account with any Times Services listed above, your opt-out of the “sale” of personal information will be specific to the browser or device from which you have clicked “Do Not Sell My Personal Information” and until you clear your cookies (or local storage in apps) on this browser or device. </p><p>If your browser or device is using a “do not track” setting, we will detect it and honor it on that specific browser or device only. If you wish to have a “do not track” experience across all of your browsers and devices, please make sure that all of your browsers and devices are set on “do not track.”</p><p>After you opt out of the “sale” of your personal information, we will no longer “sell” your personal information to third parties (except in an aggregated or de-identified manner so it is no longer personal information), but we will continue to share your personal information with our service providers, which process it on our behalf. Exercising your right to opt out of the “sale” of your personal information does not mean that you will stop seeing ads on our sites and apps. </p><p>To opt-out of interest-based advertising as much as technically possible, go to <a href="http://www.nytimes.com/privacy/cookie-policy#how-do-i-manage-trackers" target="_blank">“How Do I Manage Trackers”</a> in our Cookie Policy. To opt out of the “sale” of your personal information from participating companies, please visit the Digital Advertising Alliance <a href="https://optout.privacyrights.info/?c=1" target="_blank">website</a> or <a href="https://www.privacyrights.info/appchoices" target="_blank">apps</a>. We do not control these opt-out mechanisms and are not responsible for their operation.</p><p>You can designate someone else to make a request on your behalf. To protect your information, we will ask for a signed permission from you authorizing the other person to submit a request on your behalf. We will contact you to verify your identity before we respond to your authorized agent’s request.<p/><p>After 12 months, we may ask you if you want to opt into the “sale” of your personal information.</p><p>For further information, please refer to our <a href="http://www.nytimes.com/privacy/privacy-policy" target="_blank">Privacy Policy.</a></p>',
     "lang": 'zh-hans'
 };
 cbSectionName = "business";
 cbByline = "黄瑞黎,赫海威";</script><!-- Google Tag Manager --><script>(function(w,d,s,l,i){
     w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});
     var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';
     j.async=true;j.src='../../../../www.googletagmanager.com/gtm5445.html?id='+i+dl;
     f.parentNode.insertBefore(j,f);
 })(window,document,'script','dataLayer','GTM-KTDZV8V');</script><!-- End Google Tag Manager --><!-- chartbeat --><script type="text/javascript">var _sf_startpt=(new Date()).getTime()</script><!-- /chartbeat --><body class="news"><main class="container-fluid main clearfix"><header class="row title-bar"><div class="nav-button default" id="menuBtn"><i class="icon-bars"></i></div><h1 class="logo"><a href="/"><svg role="img" aria-label="" width="90%" height="90%"><image width="100%" height="100%" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="/d1f1eryiqyjs0r.cloudfront.net/style/imgs/mweb/nytimes-zh-hans%402x.png" src="/d1f1eryiqyjs0r.cloudfront.net/style/imgs/mweb/nytimes-zh-hans%402x.png" alt="" border="0"></image></svg></a></h1><div class="nav-button default" id="gearBtn"><i class="icon-gear"></i></div><div class="popup gear-popup"><div class="tips-container"><div class="tips-border"></div><div class="tips-inner"></div></div><div class="popup-container"><div class="popup-body"><div class="setting-title">简繁中文</div><div class="setting-option"><a href="index024e.html?changeLang=zh-hans" class="active">简体 </a><a href="index27d8.html?changeLang=zh-hant">繁体</a></div><div class="setting-title">世界经济观察报 出版语言</div><ul class="menu-list"><li><a href="https://www.nytimes.com/">ENGLISH (英语)</a></li><li><a href="https://www.nytimes.com/es/">ESPAÑOL (西班牙语)</a></li></ul><div class="setting-title">字体大小</div><div class="setting-option"><div class="form-check form-check-inline"><label class="form-check-label"><input class="form-check-input font-size" type="radio" name="changeFontSizeRadio" value="small"> 小</label></div><div class="form-check form-check-inline"><label class="form-check-label"><input class="form-check-input font-size" type="radio" name="changeFontSizeRadio" value="normal" checked="checked"> 中</label></div><div class="form-check form-check-inline"><label class="form-check-label"><input class="form-check-input font-size" type="radio" name="changeFontSizeRadio" value="large"> 大</label></div><div class="form-check form-check-inline"><label class="form-check-label"><input class="form-check-input font-size" type="radio" name="changeFontSizeRadio" value="xlarge"> 超大</label></div></div></div></div></div></header><div class="top_banner_ad" id="topad" data-target="{&quot;pos&quot;:&quot;top&quot;,&quot;adv&quot;:&quot;&quot;}"></div><div class="article-area"><div class="setting-bar row"><div class="col-4 section-title"><h3>商业与经济</h3></div><div class="col-8 setting-btns"><div class="row"><div class="col-6"><ul class="dual-btn"><li><a href="javascript:;" class="active"><span class="setting-btn-text">中文</span> <span class="setting-btn-text-mobile">中</span></a></li><li><a href="dual/index.html"><span class="setting-btn-text">中英双语</span> <span class="setting-btn-text-mobile">双语</span></a></li><li><a href="https://www.nytimes.com/2020/12/07/business/china-vaccine-astrazeneca.html" target="_blank"><span class="setting-btn-text">英文 <i class="icon-share-square"></i> </span><span class="setting-btn-text-mobile">英</span></a></li></ul></div><div class="col-6 share-tools-top-container"><ul class="share-tools mobile-article"><li><a href="http://v.t.sina.com.cn/share/share.php?&amp;title=%E4%B8%AD%E5%9B%BD%E2%80%9C%E7%96%AB%E8%8B%97%E4%B9%8B%E7%8E%8B%E2%80%9D%EF%BC%9A%E6%88%90%E5%8A%9F%E4%B8%8E%E8%B4%A2%E5%AF%8C%E5%B9%95%E5%B8%83%E4%B8%8B%E7%9A%84%E4%B8%91%E9%97%BB%E4%B8%8E%E4%BA%89%E8%AE%AE&amp;url=https://cn.nytimes.com/business/20201207/china-vaccine-astrazeneca/" target="_blank"><i class="icon-weibo"></i></a></li><!-- <li> --><!-- <a href="javascript:void(0);" class="JS_shareForQrcode" data-url="https://cn.nytimes.com/business/20201207/china-vaccine-astrazeneca/" data-headline="%E4%B8%AD%E5%9B%BD%E2%80%9C%E7%96%AB%E8%8B%97%E4%B9%8B%E7%8E%8B%E2%80%9D%EF%BC%9A%E6%88%90%E5%8A%9F%E4%B8%8E%E8%B4%A2%E5%AF%8C%E5%B9%95%E5%B8%83%E4%B8%8B%E7%9A%84%E4%B8%91%E9%97%BB%E4%B8%8E%E4%BA%89%E8%AE%AE"> --><!-- <i class="icon-wechat"></i> --><!-- </a> --><!-- </li> --><li><a href="https://www.facebook.com/sharer/sharer.php?u=https://cn.nytimes.com/business/20201207/china-vaccine-astrazeneca/" trage="_blank"><i class="icon-facebook"></i></a></li><li><a href="https://plus.google.com/share?url=https://cn.nytimes.com/business/20201207/china-vaccine-astrazeneca/" target="_blank"><i class="icon-google"></i></a></li><li><a href="https://twitter.com/share?text=%E4%B8%AD%E5%9B%BD%E2%80%9C%E7%96%AB%E8%8B%97%E4%B9%8B%E7%8E%8B%E2%80%9D%EF%BC%9A%E6%88%90%E5%8A%9F%E4%B8%8E%E8%B4%A2%E5%AF%8C%E5%B9%95%E5%B8%83%E4%B8%8B%E7%9A%84%E4%B8%91%E9%97%BB%E4%B8%8E%E4%BA%89%E8%AE%AE&amp;url=https://cn.nytimes.com/business/20201207/china-vaccine-astrazeneca/" target="_blank"><i class="icon-twitter"></i></a></li><li><div class="line-it-button" data-lang="zh_Hant" data-type="share-g" data-url="https://cn.nytimes.com/business/20201207/china-vaccine-astrazeneca/" style="display: none;"></div><script src="../../../../d.line-scdn.net/r/web/social-plugin/js/thirdparty/loader.min.js" async="async" defer="defer"></script></li><!-- <li> --><!-- <a href="javascript:void(0);" class="JS_shareForQrcode" data-url="https://cn.nytimes.com/business/20201207/china-vaccine-astrazeneca/" data-headline="%E4%B8%AD%E5%9B%BD%E2%80%9C%E7%96%AB%E8%8B%97%E4%B9%8B%E7%8E%8B%E2%80%9D%EF%BC%9A%E6%88%90%E5%8A%9F%E4%B8%8E%E8%B4%A2%E5%AF%8C%E5%B9%95%E5%B8%83%E4%B8%8B%E7%9A%84%E4%B8%91%E9%97%BB%E4%B8%8E%E4%BA%89%E8%AE%AE"> --><!-- <i class="icon-qrcode"></i> --><!-- </a> --><!-- </li> --></ul><div class="share-btn"><i class="icon-forward"></i></div></div></div></div></div><article class="article-content font-normal"><div class="article-header"><header><small></small><h1>中国“疫苗之王”：成功与财富幕布下的丑闻与争议</h1></header><div class="byline-row"><div class="byline-box"><div class="byline"><address>黄瑞黎, 赫海威</address><time pudate="2020-12-08 09:53:20" datetime="2020-12-08 09:53:20">2020年12月7日</time></div><div class="share-btn"><i class="icon-forward"></i></div></div></div></div><figure class="article-span-photo small-span-photo"><img src="/static01.nyt.com/images/2020/12/04/business/00China-vaccine-illo/00China-vaccine-illo-jumbo.html" width="755" height="1024" alt=""><figcaption><span></span> <cite>Nicolas Ortega</cite></figcaption></figure><div class="row"><div class="article-left"><section class="article-body"><div class="article-partial"><div class="article-body-item col-lg-5"><div class="article-paragraph">当一位政府监管官员侧身上车的时候，一家中国制药公司的高管将一个装有30万元现金的纸袋递了进去。</div><div class="article-paragraph">这位高管就是杜伟民，他急于让自己公司的疫苗获得批准，因此需要帮助。根据法庭文件，该官员拿走了这笔钱，并保证会尽力而为。</div><div class="article-paragraph">几个月后，杜伟民获准开始两种疫苗的临床试验。这两种疫苗最终获得批准，带来了数千万美元的收入。</div><div class="article-paragraph">2016年，该政府官员因收受杜伟民和其他几家疫苗生产商的贿赂而入狱。杜伟民从未被起诉。</div><div class="article-paragraph">相反，他建立了一个帝国。他的深圳康泰生物制品有限公司是中国最大的疫苗生产商之一。被称为“<a rel="noopener noreferrer" target="_blank" href="http://news.163.com/18/0722/17/DNB9RKDH0001899N.html">疫苗之王</a>”的杜伟民则是中国最富有的人之一。</div><div class="article-paragraph"><figure class="article-inline-photo"><div class="img-box"><img src="/static01.nyt.com/images/2020/12/04/business/00china-vaccine6/merlin_180810627_60628b67-b8f5-4931-a236-77365f077d09-master1050.html" alt="深圳康泰生物制品公司董事长杜伟民被称为“疫苗之王”，是中国最富有的人之一。" data-src="https://static01.nyt.com/images/2020/12/04/business/00china-vaccine6/merlin_180810627_60628b67-b8f5-4931-a236-77365f077d09-master1050.jpg"></div><figcaption><span>深圳康泰生物制品公司董事长杜伟民被称为“疫苗之王”，是中国最富有的人之一。</span> <cite>Yu Ga/Visual China</cite></figcaption></figure></div><div class="article-paragraph">依靠这样的成功，杜伟民和他的公司如今在<a href="https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html">新冠病毒疫苗</a>生产的<a href="https://www.nytimes.com/2020/03/19/us/politics/coronavirus-vaccine-competition.html">全球竞赛</a>中处于领先地位，这对中国共产党来说是<a href="../../20200911/china-vaccine-diplomacy/dual/index.html">国家的首要任务</a>。康泰将成为英国-瑞典合资制药巨头<a href="https://www.nytimes.com/2020/11/24/health/astrazeneca-covid-vaccine.html">阿斯利康(AstraZeneca)</a>的疫苗在中国大陆的独家生产商，这两家公司还可以在其他国家的疫苗交易上进行合作。这家中国公司也在为其候选疫苗进行早期试验。</div><div class="article-paragraph">杜伟民丑闻之下的成功在中国并非例外。而是常态。</div></div><div class="article-body-aside col-lg-3"><div id="subscribe_cont" style="margin: 0 auto;" class="container"></div></div></div><div class="big_ad" id="medium-rectangle-ad-0" data-target="{&quot;pos&quot;:&quot;mid1&quot;,&quot;adv&quot;:&quot;&quot;}"><small>广告</small></div><div class="article-partial"><div class="article-body-item col-lg-5"><div class="article-paragraph">在中国政府推动建设享誉全球的疫苗公司之际，国家扶持并保护了这个饱受<a href="../../20200506/coronavirus-china-vaccine/index.html">腐败</a>和<a href="../../20190115/china-vaccine-scandal-protests/index.html">争议</a>困扰的行业。</div><div class="article-paragraph">急于将产品送到消费者手中的制药公司利用<a href="../../20181018/china-health-care-doctors/index.html">财务激励手段</a>打动薪水微薄的政府员工，以获得监管部门的批准。查阅法庭记录显示，近年来，有数百名官员被控在涉及疫苗企业的案件中收受贿赂。牵涉其中的企业和高管很少受到惩罚。</div><div class="article-paragraph">监管的薄弱导致了大量不合格疫苗丑闻的发生。虽然政府在每次事故后都承诺要采取更多措施<a href="#https://cn.nytimes.com/china/20180724/china-vaccines-scandal-investigation/">整顿行业</a>，但监管机构很少提供关于问题出在哪里的信息。企业往往在道歉或<a href="#https://cn.nytimes.com/china/20181018/china-vaccine-fine/">支付罚款</a>之后毫发无损，而且几乎没有例外的是，它们都被允许继续经营下去。</div><div class="article-paragraph">比尔和梅琳达·盖茨基金会(Bill and Melinda Gates Foundation)前中国负责人叶雷(Ray Yip)表示，他认为康泰是中国最顶尖的疫苗企业之一，并补充说他对大多数疫苗企业的生产和技术标准“没有意见”。</div><div class="article-paragraph">“这些企业中许多的问题出在他们的商业行为上，”同时也是美国疾病控制与预防中心(U.S. Centers for Disease Control and Prevention)中国办事处负责人的叶雷说。“他们都想把产品卖给地方政府，所以必须给回扣，必须行贿。这是中国疫苗生意的致命弱点。”</div><div class="article-paragraph">康泰没有回复记者的多次置评请求。</div></div><div class="article-body-aside col-lg-3"></div></div><div class="big_ad" id="medium-rectangle-ad-1" data-target="{&quot;pos&quot;:&quot;mid2&quot;,&quot;adv&quot;:&quot;&quot;}"><small>广告</small></div><div class="article-partial"><div class="article-body-item col-lg-5"><div class="article-paragraph">阿斯利康在一份声明中表示，该公司“在与任何实体达成协议之前，都进行了妥当和彻底的尽职调查”。</div><div class="article-paragraph">“疫苗的安全性、有效性和质量至关重要，阿斯利康已与出色的知名机构合作，在疫情期间不盈利的情况下，帮助确保疫苗广泛而公平的全球可及性，”该公司表示。</div><div class="article-paragraph">缺乏透明度，再加上可疑的商业行为，动摇了公众对中国产疫苗的信心，哪怕它们已被证明是安全的。许多富裕的家长避之不及，更愿意选择西方的疫苗。</div><div class="article-paragraph">2013年，<a href="https://www.nytimes.com/2013/12/26/world/asia/china-investigates-vaccine-maker-after-infant-deaths.html">17名婴儿</a>在注射了康泰的乙肝疫苗后死亡。监管机构排除了康泰的不当行为，该疫苗仍在安全使用。但政府没有提供有关死亡事故的调查或康泰安全措施的实质性细节；该公司已经撤下了负面报道。</div><div class="article-paragraph">全世界都有忧心忡忡的父母将他们孩子的疾病或夭折<a href="https://www.nytimes.com/2019/06/18/health/vaccine-injury-claims.html">归咎于疫苗生产商</a>，这些指控往往缺乏科学证据。但在中国，政府迫使许多家庭缄口不言，进一步加深了人们对中国产疫苗的怀疑。</div><div class="article-paragraph">呼吁对包括康泰在内的制药公司进行更严格审查的活动人士遭到了骚扰、恐吓和拘留。出于对社会稳定的担忧，中国官员们试图靠封禁社交媒体群组和监控通讯来阻止他们组织活动。</div></div><div class="article-body-aside col-lg-3"></div></div><div class="big_ad" id="medium-rectangle-ad-2" data-target="{&quot;pos&quot;:&quot;mid3&quot;,&quot;adv&quot;:&quot;&quot;}"><small>广告</small></div><div class="article-partial"><div class="article-body-item col-lg-5"><div class="article-paragraph">美国对外关系委员会(Council on Foreign Relations)负责全球卫生事务的高级研究员黄严忠表示，2013年的丑闻“引发了人们”对康泰的“合理担忧”。</div><div class="article-paragraph">“风险非常高，”黄严忠说。“想象一下，如果中国再有类似丑闻被报道会怎样。这不仅会损害对生产疫苗的公司的信心，也会损害阿斯利康及其疫苗的声誉。”</div><div class="article-paragraph"><b>“疫苗之王”</b></div><div class="article-paragraph"><figure class="article-inline-photo large"><div class="img-box"><img src="/static01.nyt.com/images/2020/10/05/business/00china-vaccine-1/00china-vaccine-1-master1050.html" alt="缺乏透明度及可疑的商业行为，已经动摇了公众对中国制造的疫苗的信心。" data-src="/static01.nyt.com/images/2020/10/05/business/00china-vaccine-1/00china-vaccine-1-master1050.html"></div><figcaption><span>缺乏透明度及可疑的商业行为，已经动摇了公众对中国制造的疫苗的信心。</span> <cite>Imaginechina, via Associated Press</cite></figcaption></figure></div><div class="article-paragraph">本世纪初，在担任一家小型疫苗制造商的首席执行官时，杜伟民就在寻找增长点。他把目光投向了国外，参观了美、英、法等西方国家的制药公司和生物技术研究机构。</div><div class="article-paragraph">在接受中国媒体采访时，杜伟民回忆说，当时35岁左右的他在结束这些会面后就得出了一个紧迫的结论。杜伟民认为，中国继续依赖外国疫苗是个错误。那些疫苗太贵了。他也担心中国对其他国家的依赖会“对国家安全带来很大隐患”。</div><div class="article-paragraph">“中国人的疫苗必须牢牢地掌握在中国人的手里，”杜伟民在2014年接受国有报纸《江西日报》的采访时<a rel="noopener noreferrer" target="_blank" href="http://cpc.people.com.cn/n/2014/0408/c87228-24841556.html">表示</a>。</div></div><div class="article-body-aside col-lg-3"></div></div><div class="big_ad" id="medium-rectangle-ad-3" data-target="{&quot;pos&quot;:&quot;mid4&quot;,&quot;adv&quot;:&quot;&quot;}"><small>广告</small></div><div class="article-partial"><div class="article-body-item col-lg-5"><div class="article-paragraph">他赶上的时机非常好。多年来依靠跨国企业提供关键药品的中国政府，出于许多相同的原因，希望培育本土疫苗产业。</div><div class="article-paragraph">从毛时代开始，国有企业长期主导着中国的商业。随着需求增长，杜伟民这样的企业家就看到了建立具有<a href="#https://cn.nytimes.com/usa/20200312/dc-virus-drug/">全球竞争力</a>的企业的机会。</div><div class="article-paragraph">许多企业都愿意与外国疫苗制造商合作，这一战略也被中国在科技和汽车制造等其他领域采用。这些跨国企业获得了进入中国市场的机会，而中国企业则获得了有关生产工艺和技术的宝贵知识。</div><div class="article-paragraph">这样的交易，让杜伟民这个来自江西省贫困山区农民家庭的儿子得以登上更大的舞台。</div><div class="article-paragraph">2004年，他帮助成立了北京民海生物科技有限公司，之后与法国制药巨头赛诺菲巴斯德(Sanofi Pasteur)合作研制狂犬病疫苗。当时，中国政府正在号召齐心协力控制该疾病的蔓延，那一年，狂犬病在中国造成2600多人死亡。</div><div class="article-paragraph">2008年，杜伟民投资康泰，扩大了自己的业务。这家公司于1992年在美国制药商默克(Merck)的帮助下成立。作为旨在提高中国卫生标准的共同行动的一部分，他们联合生产了一种乙肝疫苗。</div></div><div class="article-body-aside col-lg-3"></div></div><div class="big_ad" id="medium-rectangle-ad-4" data-target="{&quot;pos&quot;:&quot;mid5&quot;,&quot;adv&quot;:&quot;&quot;}"><small>广告</small></div><div class="article-partial"><div class="article-body-item col-lg-5"><div class="article-paragraph">他的交易手段将创造出一个行业巨头。当地媒体称他是“<a rel="noopener noreferrer" target="_blank" href="http://cpc.people.com.cn/n/2014/0408/c87228-24841556.html?from=timeline&amp;from=1087293010&amp;weiboauthoruid=">疫苗王国的勇士</a>”。</div><div class="article-paragraph">截至今年5月，他的净资产估值达到74亿美元，他也在此时将价值35亿美元的公司股份转给了前妻袁莉萍，中国媒体将此举称为中国有史以来最昂贵的离婚。袁莉萍是加拿大公民，如今已经成为加拿大最为富有的女性之一。</div><div class="article-paragraph">“从发家、暴富到离婚，”大陆新闻网站华夏时报网在关于这位大亨的报道中写道，“他身上的谜，只能交给时间来解答。”</div><div class="article-paragraph"><b>资本铁腕</b></div><div class="article-paragraph"><figure class="article-inline-photo large"><div class="img-box"><img src="/static01.nyt.com/images/2020/10/05/business/00china-vaccines-3/merlin_143674044_b137f7f5-3e14-485f-ab6c-fdf3a3d8972c-master1050.html" alt="调查记者杜涛欣在写了一篇批评杜伟民和中国药品监管部门的文章后，被判诽谤罪。他已经离开了新闻界。“疫苗好像一件不可碰的事情，”他说。" data-src="/static01.nyt.com/images/2020/10/05/business/00china-vaccines-3/merlin_143674044_b137f7f5-3e14-485f-ab6c-fdf3a3d8972c-master1050.html"></div><figcaption><span>调查记者杜涛欣在写了一篇批评杜伟民和中国药品监管部门的文章后，被判诽谤罪。他已经离开了新闻界。“疫苗好像一件不可碰的事情，”他说。</span> <cite>Giulia Marchi</cite></figcaption></figure></div><div class="article-paragraph">时机看上去有些可疑。</div><div class="article-paragraph">2010年，国营报纸《中国青年报》<a rel="noopener noreferrer" target="_blank" href="http://zqb.cyol.com/content/2010-04/05/content_3167311.htm">报道</a>称，监管机构没有及时将约有18万剂狂犬病疫苗无效的信息告知公众。这些疫苗由江苏延申生产，该公司当时为康泰生物的杜伟民所有。</div><div class="article-paragraph">据财经新闻媒体《经济观察报》网站报道，在长达9个月的拖延中，杜伟民将这家公司约51%的股份卖给了另一家制药商先声药业集团。</div><div class="article-paragraph">调查记者杜涛欣开始挖掘内幕。他表示，业内人士证实了这些报道，并告诉他，监管机构推迟发布公告，是为了让杜伟民出售股份，从而不用为丑闻承担责任。</div><div class="article-paragraph">这与有政府背景的中国中央人民广播电台的<a rel="noopener noreferrer" target="_blank" href="http://finance.cnr.cn/txcj/201409/t20140918_516458658.shtml">报道</a>一致。该篇文章同样提到了杜伟民的名字，并发现当局隐瞒了这一信息，以使先声药业不得不承担丑闻带来的名誉损失。</div><div class="article-paragraph">在疫苗问题被曝光后，先声药业发布声明称，疫苗质量问题发生在其成为江苏延申的股东之前，强调称自己与“本次事件没有任何责任关联”。作为江苏延申的高管，杜伟民没有置评。</div><div class="article-paragraph">2014年8月，这位记者以《食药监总局官员身陷“举报门”疫苗案大起底》为标题发表了文章。</div><div class="article-paragraph">该行业的许多问题都是与政府的共生关系导致的。中国的疫苗由地方传染病控制中心进行管理。这些中心要从某些类型疫苗的利润分一杯羹，为<a href="https://www.nytimes.com/2016/11/02/business/international/china-rules-glaxo-bribes-sex-tape-whistleblower-cautionary-tale.html">腐败</a>创造了诱因。</div><div class="article-paragraph">根据《世界经济观察报》的一项分析，从2018年到2020年，共有59起涉及疫苗企业的腐败诉讼。其中54起涉及贿赂地方官员。</div><div class="article-paragraph">康泰对记者杜涛欣及其工作的报社《民主与法制时报》提起诉讼，称其诽谤。</div><div class="article-paragraph">杜涛欣及报社试图为自己的作品辩护，提交了在他们看来是媒体压力的其他证据。</div><div class="article-paragraph">2014年9月，官方电视台广东卫视的一个节目中，一名著名中国经济学家批评了这位大亨的企业。电视台随后就节目造成的“精神损害”向杜伟民道歉，并撤回了报道。</div><div class="article-paragraph">法庭文件显示，具有影响力的商业报纸《21世纪经济报道》删除了其发表过的七篇文章，这些文章均与杜伟民的公司及2013年接种康泰乙肝疫苗新生儿死亡有关。该报密切报道了几起死亡事件，并且报道称杜伟民一家此前已移民加拿大。</div><div class="article-paragraph">作为其辩护的一部分，记者指出中国人民广播电台也对同一题材进行过报道。尚不清楚为何这些媒体没有面临法律行动。</div><div class="article-paragraph">这位疫苗大亨的律师是张合，他还为国家食药监局领导尹红章辩护过，后者因为收受杜伟民贿赂被定罪。</div><div class="article-paragraph">杜涛欣认为，这起受贿案可以证明，他的文章没有对这位高管进行诽谤。在法庭文件中，杜伟民承认他正是曾向尹红章行贿的“杜某”。</div><div class="article-paragraph">但法官表示，这一信息与该案无关。在进行裁决时，该法官还将该名记者拒绝披露其匿名信源的身份作为根据。</div><div class="article-paragraph">2016年11月，杜涛欣被判“侵害”杜伟民“名誉权”。法院表示杜涛欣的文章“导致杜伟民的社会评价降低，侵害了其名誉权”。</div><div class="article-paragraph">他必须要赔偿杜伟民2000元人民币，报社必须删除报道。</div><div class="article-paragraph">这一判决是在中国记者节当天发出的。一年后，杜涛欣辞职不做记者了。</div><div class="article-paragraph">“疫苗好像一件不可碰的事情，”杜涛欣说。“无论我怎么坚持追逐地真相，真相好像是不可能的事情。我拿出所有的证据，但我知道这是一场不可能打赢的官司。”</div><div class="article-paragraph"><b>优待</b><br></div><div class="article-paragraph">近年来，一批中国家庭牵头发起了一项<a href="#https://cn.nytimes.com/china/20180731/china-protest-faulty-vaccines/">规模不大但坚定的行动</a>，试图让这个国家的疫苗行业得到更严格监管。将<a href="https://www.nytimes.com/2015/07/23/world/asia/china-crackdown-human-rights-lawyers.html">政治组织</a>视为对共产党威胁的政府已经在寻求让他们的活动噤声。</div><div class="article-paragraph">官员已经骚扰、拘留了孩子们的母亲、父亲和祖母，指控他们“扰乱公共秩序”或“寻衅滋事”。据其朋友说，10月，河南省当局拘留了何方美。她是中国最直言不讳批评中国疫苗公司的人之一。鉴于法律敏感性，她的朋友要求匿名。</div><div class="article-paragraph">为疫苗活动人士代理案件的律师面临严重处罚。许多家庭用来倾诉不满和协调抗议的微信群被关停。</div><div class="article-paragraph"><figure class="article-inline-photo large"><div class="img-box"><img src="/static01.nyt.com/images/2020/10/05/business/00china-vaccine-2/00china-vaccine-2-master1050.html" alt="深圳康泰生物制品公司生产的疫苗供应量约占全球的四分之一。" data-src="/static01.nyt.com/images/2020/10/05/business/00china-vaccine-2/00china-vaccine-2-master1050.html"></div><figcaption><span>深圳康泰生物制品公司生产的疫苗供应量约占全球的四分之一。</span> <cite>Imaginechina, via Associated Press</cite></figcaption></figure></div><div class="article-paragraph">在儿子彭勇（音）被发现患有病毒性脑炎后，廖方生（音）试图向中央政府请愿。廖方生说，在儿子接种康泰生产的疫苗前，他是一个快乐健康的一岁半宝宝。</div><div class="article-paragraph">在接种两到三天后，彭勇出现低烧，随后陷入昏迷长达17天。2019年12月，当地卫健委表示这名男孩接种疫苗后生病是个“巧合”。</div><div class="article-paragraph">廖方生没有科学方面的证据，但他仍然相信此事与疫苗有关。他前往北京的国家卫健委和信访局。他们把他推给了其他政府部门，廖认为这是“推诿扯皮”。</div><div class="article-paragraph">他试图在中国共产党领导人大院外寻求帮助，结果被送回自己的家乡江西省拘留一周。一份拘留通知书显示，当局说他“扰乱单位秩序”。</div><div class="article-paragraph">“他们都是穿一条裤子，上级保护下级，”廖方生说。“交的才材料没人看。我说话的地方都没有。你说这个法律在哪里？政府在哪里？”</div><div class="article-paragraph">中国政府保护这个行业不受批评可能是有原因的。在一个有着14亿人口的国家，谣言传播得很快。但信息匮乏和法律资源的缺失也可能会滋生深深的不信任感。<br></div><div class="article-paragraph">2010年，中国南部广东省有数十名小学生在注射康泰的乙肝疫苗后出现头疼、呕吐和四肢无力问题。</div><div class="article-paragraph">据官方新闻机构新华社报道，一名省卫生官员将问题归咎于“群体性心因性反应”。</div><div class="article-paragraph">这位名叫彭国文的官员是广东省疾控中心计划免疫所所长，他说像头晕或腹痛这样的症状大多是“主观的”，并且这些学生都没有出现发烧。他指责媒体和社会上散布的有关疫苗安全性的谣言，称这“加剧”了学生的紧张情绪，从而导致呕吐。</div><div class="article-paragraph">在另一场新闻发布会上，一名记者问政府如何在没有得到检测结果的情况下就判断不良反应与疫苗无关。据《南方都市报》报道，官员们没有回答。</div><div class="article-paragraph">2013年，有报道称17名婴儿在接种了同一种疫苗后死亡，杜伟民被中国媒体和民众称为“杀婴者”。政府在12月叫停了疫苗的销售，时间持续逾一个月。</div><div class="article-paragraph">在认定责任不在该公司后，政府取消了禁令。官方公布的调查结果没有透露多少细节。据一份政府声明称，报告主要是表示了解到死亡事件的发生，并列出死因，包括肺炎、心脏病和腹泻。</div><div class="article-paragraph">相比其他国家，中国一直在疫苗安全性的问题上不太透明。在美国，联邦政府在生产商报告疫苗问题后通常会委托进行深度评估。在韩国，近期有一系列死亡事件导致一种流感疫苗遭遇信任危机，政府随即就死亡案例公布了<a href="https://www.nytimes.com/2020/11/24/world/asia/korea-flu-vaccine-coronavirus-scare.html">详细的数据</a>，以恢复公众的信心。</div><div class="article-paragraph">如今中国正在努力建立科学和医学大国的国际声誉，疫苗生产商的声誉问题变得空前重要。</div><div class="article-paragraph">几十年来，这个产业一直侧重于在国内销售产品，认为国内市场的规模足以维持运转。很少有公司开发出能产生国际影响的产品。</div><div class="article-paragraph">只有五种中国疫苗得到了世卫组织的出口预审批。相比之下，印度有47种疫苗达到了这一要求。</div><div class="article-paragraph">在中国，<a href="https://www.nytimes.com/2020/11/17/business/china-coronavirus-vaccine-safety.html">新冠疫情</a>给这个产业带来了走向世界的机遇——它正在向康泰这样的领先企业注入巨资。</div><div class="article-paragraph">南方城市深圳的地方政府给了康泰一块20000平方米的地，用于建造公司的新冠疫苗工厂。康泰还得到了中国为防疫工作拨发的经费。</div><div class="article-paragraph">阿斯利康和牛津大学上月底宣布，他们的疫苗看起来是有效的，尽管有效水平存在争议。根据与阿斯利康的协议，康泰将为中国大陆生产2亿剂疫苗。</div><div class="article-paragraph">9月底，康泰宣布在中国开展自己研发的新冠疫苗的测试，此前该疫苗经实验证明对鼠、猴能起到保护作用。</div><div class="article-paragraph">在接受官方媒体中央电视台采访时，康泰首席科学家郑海发表示，公司正力争“尽快”在疫苗研发上实现突破，以完成国家最高领导人习近平交予的任务，后者曾呼吁全国药企开展疫苗生产的全面行动。</div><div class="article-paragraph">郑海发说，公司的使命很简单：“为人民生命健康安全提供有效保障。”</div></div><div class="article-body-aside col-lg-3"></div></div></section><footer class="author-info"><p>Katie Thomas对本文有报道贡献。Elsie Chen、Amber Wang、Liu Yi、Albee Zhang对本文有研究贡献。</p><p>黄瑞黎(Sui-Lee Wee)是《世界经济观察报》驻北京分社记者。她报道中国近十年，关注社会议题、性别、基因监测、医疗保健以及人口和经济的交叉议题。欢迎在Twitter上关注她 <a rel="nofollow" target="_blank" href="https://twitter.com/suilee">@suilee</a>。</p><p>赫海威(Javier C. Hernández)是《世界经济观察报》负责报道中国的记者。他报道了习近平领导下专制国家的崛起、#MeToo运动等社会理念的发展以及农民工和污染受害者等中国最弱势公民的困境。欢迎在Twitter上关注他<a rel="nofollow" target="_blank" href="https://twitter.com/HernandezJavier"> @HernandezJavier</a>。</p><p>翻译：世界经济观察报中文网</p><p><a rel="nofollow" target="_blank" href="https://www.nytimes.com/2020/12/07/business/china-vaccine-astrazeneca.html">点击查看本文英文版。</a></p></footer></div></div></article><div class="container article-footer"><div class="row"><div class="col-lg-12 mobile-refer-cont" id="J_hideRefer"><div class="related-cont"><h4>相关报道</h4><ul class="refer-list"><li class="article-refer"><div class="refer-list-item"><a href="../../20200928/china-coronavirus-vaccine/index.html" title="中国豪赌新冠疫苗，数万人已接种"><div><h3 class="refer-list-headline">中国豪赌新冠疫苗，数万人已接种</h3><p class="refer-pubdate">2020年9月28日</p></div><img alt="中国豪赌新冠疫苗，数万人已接种" src="/static01.nyt.com/images/2020/09/24/business/00china-vaccines-4/00china-vaccines-4-thumbLarge.html" width="75" height="75"></a></div></li><li class="article-refer"><div class="refer-list-item"><a href="#https://cn.nytimes.com/asia-pacific/20201125/korea-flu-vaccine-coronavirus-scare/" title="韩国流感疫苗恐慌给世界的宝贵一课"><div><h3 class="refer-list-headline">韩国流感疫苗恐慌给世界的宝贵一课</h3><p class="refer-pubdate">2020年11月25日</p></div><img alt="韩国流感疫苗恐慌给世界的宝贵一课" src="/static01.nyt.com/images/2020/11/23/world/00skorea-vaccine01/00skorea-vaccine01-thumbLarge.html" width="75" height="75"></a></div></li><li class="article-refer"><div class="refer-list-item"><a href="#https://cn.nytimes.com/china/20181018/china-vaccine-fine/" title="中国对假疫苗制造商开巨额罚单"><div><h3 class="refer-list-headline">中国对假疫苗制造商开巨额罚单</h3><p class="refer-pubdate">2018年10月18日</p></div><img alt="中国对假疫苗制造商开巨额罚单" src="/static01.nyt.com/images/2018/10/18/world/18Chinavaccine1/18Chinavaccine1-thumbLarge.html" width="75" height="75"></a></div></li><li class="article-refer"><div class="refer-list-item"><a href="#https://cn.nytimes.com/china/20180820/china-vaccines-scandal/" title="中国疫苗丑闻10名涉事官员遭免职"><div><h3 class="refer-list-headline">中国疫苗丑闻10名涉事官员遭免职</h3><p class="refer-pubdate">2018年8月20日</p></div><img alt="中国疫苗丑闻10名涉事官员遭免职" src="/static01.nyt.com/images/2018/08/18/world/18china-vaccine/18china-vaccine-thumbLarge.html" width="75" height="75"></a></div></li><li class="article-refer"><div class="refer-list-item"><a href="#https://cn.nytimes.com/china/20160419/c19chinavaccine/" title="疫苗事件再次拷问中国政府公信力"><div><h3 class="refer-list-headline">疫苗事件再次拷问中国政府公信力</h3><p class="refer-pubdate">2016年4月19日</p></div><img alt="疫苗事件再次拷问中国政府公信力" src="/static01.nyt.com/images/2016/04/15/world/xxCHINA-VACCINE-web1/xxCHINA-VACCINE-web1-thumbLarge.html" width="75" height="75"></a></div></li></ul></div></div><div class="col-lg-12"><div class="related hot_article"><h5 class="related-title">最受欢迎</h5><ol class="related-articles"><li><a href="#https://cn.nytimes.com/usa/20220127/computer-chip-shortage-taiwan/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>战棋推演报告称台湾半导体工厂停产可能引发中美冲突</h4><img alt="战棋推演报告称台湾半导体工厂停产可能引发中美冲突" src="/static01.nyt.com/images/2022/01/26/us/politics/26dc-wargames/merlin_177315390_5fcf8532-e370-4f81-8f99-45c6c83044f4-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/opinion/20220127/pakistan-united-states-china/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>“巴铁”军方为什么想与中国保持距离？</h4><img alt="“巴铁”军方为什么想与中国保持距离？" src="/static01.nyt.com/images/2022/01/24/opinion/21Rafiq1/21Rafiq1-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/china/20220128/china-fight-club-ending/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>《搏击俱乐部》结局遭篡改，中国审查制度再掀争议</h4><img alt="《搏击俱乐部》结局遭篡改，中国审查制度再掀争议" src="/static01.nyt.com/images/2022/01/27/multimedia/27xp-china-fightclub/27xp-china-fightclub-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/opinion/20220126/china-covid-19/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>中国追求“清零”将把国家置于灾难之中</h4><img alt="中国追求“清零”将把国家置于灾难之中" src="/static01.nyt.com/images/2022/01/25/opinion/25emanuel/25emanuel-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/sports/20220127/peng-shuai-china-australian-open/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>澳网再现“彭帅在哪里”：球员和观赛者拒绝遗忘、为其发声</h4><img alt="澳网再现“彭帅在哪里”：球员和观赛者拒绝遗忘、为其发声" src="/static01.nyt.com/images/2022/01/26/sports/26aus-china1/merlin_199503951_9c695f25-2b8e-41b4-9c97-bf91de7aa190-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/usa/20220128/selective-high-schools-brooklyn-tech/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>作为亚裔学生就读纽约精英高中，是一种什么样的体验</h4><img alt="作为亚裔学生就读纽约精英高中，是一种什么样的体验" src="/static01.nyt.com/images/2022/01/17/us/17schools-selective1/merlin_200009688_449611ef-4c11-43d4-a6f2-e74b0066acdf-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/opinion/20220127/virtual-reality-simulation/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>我们可能活在模拟现实中，人类应该多担忧这件事？</h4><img alt="我们可能活在模拟现实中，人类应该多担忧这件事？" src="/static01.nyt.com/images/2022/01/26/opinion/26manjoo-image/26manjoo-image-thumbLarge.jpg"></article></a></li><li><a href="../../20220128/olympic-sponsors-china-beijing/indexf61c.html?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>“中国是个例外”：为何国际赞助商不愿抵制北京冬奥会</h4><img alt="“中国是个例外”：为何国际赞助商不愿抵制北京冬奥会" src="/static01.nyt.com/images/2022/01/26/world/OLYMPIC-SPONSORS-01/OLYMPIC-SPONSORS-01-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/usa/20220125/gang-chen-mit-china/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>“我们在残害我们自己”：华裔教授陈刚案背后的愤怒与幻灭</h4><img alt="“我们在残害我们自己”：华裔教授陈刚案背后的愤怒与幻灭" src="/static01.nyt.com/images/2022/01/24/science/24CHEN-promo/24CHEN-promo-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/china/20220124/winter-olympics-china-beijing-xi-jinping/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>不再取悦世界：一届展现习近平全面愿景的冬奥会</h4><img alt="不再取悦世界：一届展现习近平全面愿景的冬奥会" src="/static01.nyt.com/images/2022/01/13/world/00xi-olympics-30/00xi-olympics-30-thumbLarge.jpg"></article></a></li></ol></div></div></div></div></div><footer class="row copy-footer">&copy; 2022 The World Economy Observer.<ul class="footerLinkList"><li class="footerLink"><a rel="nofollow" href="/ad/">广告</a></li><li class="footerLink"><a rel="nofollow" href="/about-us/">关于我们</a></li><li class="footerLink"><a rel="nofollow" href="/contact/">联系我们</a></li><li class="footerLink"><a rel="nofollow" href="/tos/">服务条款</a></li><li class="purr-content"></li></ul></footer><script src="/d1f1eryiqyjs0r.cloudfront.net/js/libs/require619b.js?v=f1810d8"></script><script src="/d1f1eryiqyjs0r.cloudfront.net/js/web/article.min619b.js?v=f1810d8"></script></main></body>
<!-- Mirrored from cn.nytimes.com/business/20201207/china-vaccine-astrazeneca/ by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 28 Jan 2022 14:09:06 GMT -->
</html>